CH672733A5 - - Google Patents
Download PDFInfo
- Publication number
- CH672733A5 CH672733A5 CH1991/87A CH199187A CH672733A5 CH 672733 A5 CH672733 A5 CH 672733A5 CH 1991/87 A CH1991/87 A CH 1991/87A CH 199187 A CH199187 A CH 199187A CH 672733 A5 CH672733 A5 CH 672733A5
- Authority
- CH
- Switzerland
- Prior art keywords
- vesicles
- iodine
- liposomes
- encapsulated
- aqueous
- Prior art date
Links
- 239000002502 liposome Substances 0.000 claims abstract description 79
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 70
- 239000011630 iodine Substances 0.000 claims abstract description 70
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 68
- 150000002632 lipids Chemical class 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 239000012528 membrane Substances 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 210000000056 organ Anatomy 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 51
- 239000000725 suspension Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 22
- 238000001125 extrusion Methods 0.000 claims description 14
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 13
- 229960004647 iopamidol Drugs 0.000 claims description 12
- 238000005538 encapsulation Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 6
- -1 io-meprol Chemical compound 0.000 claims description 6
- 238000001471 micro-filtration Methods 0.000 claims description 6
- 238000010606 normalization Methods 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 239000002612 dispersion medium Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000005199 ultracentrifugation Methods 0.000 claims description 3
- 229960001025 iohexol Drugs 0.000 claims description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims 2
- KZYHGCLDUQBASN-UHFFFAOYSA-N 1-n,1-n,3-n,3-n,5-n,5-n-hexakis(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3,5-tricarboxamide Chemical compound OCCN(CCO)C(=O)C1=C(I)C(C(=O)N(CCO)CCO)=C(I)C(C(=O)N(CCO)CCO)=C1I KZYHGCLDUQBASN-UHFFFAOYSA-N 0.000 claims 1
- OQHLOKBHRXMXLD-UHFFFAOYSA-N 5-[3-[3-[3,5-bis[2,3-dihydroxypropyl(methyl)carbamoyl]-2,4,6-triiodoanilino]-3-oxopropyl]sulfanylpropanoylamino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(C(=O)N(CC(O)CO)C)=C(I)C(NC(=O)CCSCCC(=O)NC=2C(=C(C(=O)N(C)CC(O)CO)C(I)=C(C(=O)N(C)CC(O)CO)C=2I)I)=C1I OQHLOKBHRXMXLD-UHFFFAOYSA-N 0.000 claims 1
- RHISTIGVAKTTCM-UHFFFAOYSA-N 5-[[3-[3,5-bis(1,3-dihydroxypropan-2-ylcarbamoyl)-n-(2-hydroxyethyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2-hydroxyethyl)amino]-1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C(I)C=1N(CCO)C(=O)CC(=O)N(CCO)C1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I RHISTIGVAKTTCM-UHFFFAOYSA-N 0.000 claims 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 229950002407 iodecimol Drugs 0.000 claims 1
- 229960004359 iodixanol Drugs 0.000 claims 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims 1
- 229960000824 iopentol Drugs 0.000 claims 1
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002603 iopromide Drugs 0.000 claims 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims 1
- 229950011065 iosimide Drugs 0.000 claims 1
- 229950011097 iotasul Drugs 0.000 claims 1
- 229960004537 ioversol Drugs 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- 229940067631 phospholipid Drugs 0.000 description 13
- 150000003904 phospholipids Chemical class 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 7
- 239000003605 opacifier Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229960005423 diatrizoate Drugs 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002497 iodine compounds Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 229960005223 diatrizoic acid Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- XQZXYNRDCRIARQ-UHFFFAOYSA-N 1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-5-(2-hydroxypropanoylamino)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound CC(O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-UHFFFAOYSA-N 0.000 description 1
- OIXRDAZPDINJPT-UHFFFAOYSA-N 2,4,6-triiodo-3,5-bis(propanoylamino)benzoic acid Chemical compound CCC(=O)NC1=C(I)C(NC(=O)CC)=C(I)C(C(O)=O)=C1I OIXRDAZPDINJPT-UHFFFAOYSA-N 0.000 description 1
- CORFWQGVBFFZHF-UHFFFAOYSA-N 2-iodohippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1I CORFWQGVBFFZHF-UHFFFAOYSA-N 0.000 description 1
- QXXSPCOLSLNNNE-UHFFFAOYSA-N 3,5-diiodo-1-methyl-4-oxopyridine-2,6-dicarboxylic acid Chemical compound CN1C(C(O)=O)=C(I)C(=O)C(I)=C1C(O)=O QXXSPCOLSLNNNE-UHFFFAOYSA-N 0.000 description 1
- GNOGSFBXBWBTIG-UHFFFAOYSA-N Acetrizoic acid Chemical compound CC(=O)NC1=C(I)C=C(I)C(C(O)=O)=C1I GNOGSFBXBWBTIG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 1
- ZFHZUGUCWJVEQC-FPUQOWELSA-M Ipodate Sodium Chemical compound [Na+].CN(C)\C=N\C1=C(I)C=C(I)C(CCC([O-])=O)=C1I ZFHZUGUCWJVEQC-FPUQOWELSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- KTVKGXZZBQCBGD-UHFFFAOYSA-M Tyropanoate sodium Chemical compound [Na+].CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C([O-])=O)=C1I KTVKGXZZBQCBGD-UHFFFAOYSA-M 0.000 description 1
- SWJBITNFDYHWBU-UHFFFAOYSA-N [I].[I] Chemical compound [I].[I] SWJBITNFDYHWBU-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229960005216 acetrizoic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- RERHJVNYJKZHLJ-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;2-(3,5-diiodo-4-oxopyridin-1-yl)acetate Chemical compound OCCNCCO.OC(=O)CN1C=C(I)C(=O)C(I)=C1 RERHJVNYJKZHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- PVBALTLWZVEAIO-UHFFFAOYSA-N diodone Chemical compound OC(=O)CN1C=C(I)C(=O)C(I)=C1 PVBALTLWZVEAIO-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- SIZXNBZGPPPFHM-UHFFFAOYSA-L disodium;3-[[6-(3-carboxylato-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C([O-])=O)C(I)=CC=2I)I)=C1I SIZXNBZGPPPFHM-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
- 229960004901 iodamide Drugs 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- DGIAUNUPXILTJW-VRWDCWMNSA-N iodipamide dimeglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I DGIAUNUPXILTJW-VRWDCWMNSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229960003182 iotrolan Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940100477 meglumine iodipamide Drugs 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 1
- 229960003037 sodium tyropanoate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000004876 x-ray fluorescence Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1991/87A CH672733A5 (US07261876-20070828-C00017.png) | 1987-05-22 | 1987-05-22 | |
| AU18054/88A AU612371B2 (en) | 1987-05-22 | 1988-05-16 | Injectable opacifying liposome composition |
| US07/302,690 US5312615A (en) | 1987-05-22 | 1988-05-16 | Injectable opacifying composition containing liposomes of high encapsulation capacity for X-ray examinations |
| JP63504697A JP2619037B2 (ja) | 1987-05-22 | 1988-05-16 | Ｘ線検査用の高封入容量のリポソームを含有する注射可能な不透明組成物 |
| AT88904952T ATE80294T1 (de) | 1987-05-22 | 1988-05-16 | Injizierbare, opazifizierende liposomzusammensetzung. |
| EP88904952A EP0314764B2 (en) | 1987-05-22 | 1988-05-16 | Injectable opacifying liposome composition |
| ZA883449A ZA883449B (en) | 1987-05-22 | 1988-05-16 | Injectable opacifying composition containing liposomes of high encapsulation capacity of x-ray examinations |
| PCT/EP1988/000447 WO1988009165A1 (en) | 1987-05-22 | 1988-05-16 | Injectable opacifying liposome composition |
| DE3874485T DE3874485T3 (de) | 1987-05-22 | 1988-05-16 | Injizierbare, opazifizierende liposomzusammensetzung. |
| IL86409A IL86409A (en) | 1987-05-22 | 1988-05-17 | Injectable x-ray opacifying liposome compositions |
| CA000567314A CA1303978C (en) | 1987-05-22 | 1988-05-20 | Injectable opacifying composition containing liposomes of high encapsulation capacity for x-ray examinations |
| ES8801604A ES2009917A6 (es) | 1987-05-22 | 1988-05-20 | Composicion opacificante inyectable para examenes con rayos x, que contiene liposomas con elevada capacidad de encapsulado. |
| MX9203271A MX9203271A (es) | 1987-05-22 | 1992-06-24 | Composicion opascificante inyectable para examenes con rayos x. |
| US08/128,206 US5445810A (en) | 1987-05-22 | 1993-09-29 | Injectable opacifying composition containing liposomes of high encapsulating capacity for X-ray examinations |
| US08/440,134 US5626832A (en) | 1987-05-22 | 1995-05-12 | Injectable opacifying composition containing liposomes of high encapsulation capacity for X-ray examinations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1991/87A CH672733A5 (US07261876-20070828-C00017.png) | 1987-05-22 | 1987-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH672733A5 true CH672733A5 (US07261876-20070828-C00017.png) | 1989-12-29 |
Family
ID=4223355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1991/87A CH672733A5 (US07261876-20070828-C00017.png) | 1987-05-22 | 1987-05-22 |
Country Status (13)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH672733A5 (US07261876-20070828-C00017.png) * | 1987-05-22 | 1989-12-29 | Bracco Ind Chimica Spa | |
| MX9203504A (es) * | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5820848A (en) * | 1990-01-12 | 1998-10-13 | The Liposome Company, Inc. | Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent |
| US6613306B1 (en) * | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| IN172208B (US07261876-20070828-C00017.png) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
| US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
| US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| IS1685B (is) * | 1990-12-11 | 1998-02-24 | Bracco International B.V. | Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum |
| US5447635A (en) * | 1991-02-26 | 1995-09-05 | Bracco International B.V. | Process of concentration and purification of organic compounds |
| US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
| SE470086B (sv) * | 1991-04-23 | 1993-11-08 | Kabi Pharmacia Ab | Organspecifik emulsion |
| SE9101709L (sv) * | 1991-06-03 | 1992-12-04 | Karlshamns Lipidteknik Ab | Lipidderivat som diagnostikum eller kontrastmedel |
| IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
| CA2146963A1 (en) * | 1992-10-16 | 1994-04-28 | Andreas Sachse | Process and device for producing liquid, dispersed systems |
| DE1118326T1 (de) * | 1993-05-21 | 2002-04-18 | Liposome Co Inc | Reduzierung von durch Liposomen induzierten physiologischen Gegenreaktionen |
| US6217849B1 (en) | 1993-09-29 | 2001-04-17 | Bracco Research S.A. | Liposome suspensions as blood pool imaging contrast agents |
| CN1068229C (zh) * | 1993-12-15 | 2001-07-11 | 勃勒柯研究有限公司 | 超声对比介质、含该介质的对比剂及方法 |
| CN1148812A (zh) * | 1994-03-28 | 1997-04-30 | 尼科梅德成像有限公司 | “脂质体” |
| US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| DE69616453T2 (de) * | 1995-02-24 | 2002-07-11 | Bracco Research Sa | Liposomensuspensionen als blut-pool-kontrastmittel |
| DE19518221A1 (de) * | 1995-05-10 | 1996-11-14 | Schering Ag | Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen |
| US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| JP2001507207A (ja) | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 化合物を細胞に送達する方法 |
| US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| JP4109780B2 (ja) | 1998-03-06 | 2008-07-02 | 株式会社東海理化電機製作所 | ギヤ機構及びウエビング巻取装置 |
| WO1999049849A1 (en) * | 1998-03-31 | 1999-10-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal bupivacaine compositions and methods of preparation |
| US6706280B2 (en) * | 1998-08-19 | 2004-03-16 | Bracco Research S.A. | Carboxylated phosphatidic acid esters |
| JP3980777B2 (ja) | 1998-11-02 | 2007-09-26 | 株式会社東海理化電機製作所 | ウエビング巻取装置 |
| US6426145B1 (en) | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
| EP1180018B1 (en) | 1999-05-27 | 2005-03-02 | Euro-Celtique S.A. | Use of antiseptics in the manufacture of a pharmaceutical preparation for the prevention and treatment of infections and/ or functional tissue remodelling in the interior of the human body |
| US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
| US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
| EP1289565B1 (en) | 2000-06-02 | 2015-04-22 | Bracco Suisse SA | Compounds for targeting endothelial cells |
| JP2005170928A (ja) * | 2003-10-21 | 2005-06-30 | Konica Minolta Medical & Graphic Inc | リポソーム含有ｘ線造影剤およびその製造方法 |
| JP2005170923A (ja) * | 2003-10-21 | 2005-06-30 | Konica Minolta Medical & Graphic Inc | リポソーム含有ｘ線造影剤およびその製造方法 |
| JP4654590B2 (ja) * | 2004-03-31 | 2011-03-23 | コニカミノルタエムジー株式会社 | Ｘ線ｃｔ用造影組成物およびその製造方法 |
| US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
| US7713517B2 (en) * | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
| EP1772156A1 (en) * | 2004-07-21 | 2007-04-11 | Konica Minolta Medical & Graphic, Inc. | Liposome-containing x-ray radiopaque dye and process for producing the same |
| JP5176320B2 (ja) * | 2004-08-11 | 2013-04-03 | コニカミノルタエムジー株式会社 | リポソーム含有製剤の製造方法 |
| US20060110439A1 (en) * | 2004-10-22 | 2006-05-25 | Dynamis Therapeutics, Inc. | Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds |
| WO2007129311A2 (en) * | 2006-05-04 | 2007-11-15 | Pan Sci Tech S.A. | Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct |
| EP2217146A4 (en) * | 2007-12-05 | 2015-10-14 | Marval Biosciences Inc | NANOMETRIC SCALE CONTRAST AGENTS AND METHODS OF USE |
| US20090311191A1 (en) * | 2008-06-13 | 2009-12-17 | Ananth Annapragada | Imaging of atherosclerotic plaques using liposomal imaging agents |
| CN102438591A (zh) * | 2009-03-19 | 2012-05-02 | 马维尔生物科学公司 | 用于增强成像对比度的组合物和方法 |
| US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
| IT1404011B1 (it) | 2010-12-03 | 2013-11-08 | Uni Degli Studi Magna Graecia Di Catanzaro | Nanovettore coniugato con tsh per il trattamento del cancro della tiroide |
| FR3017295B1 (fr) * | 2014-02-07 | 2018-01-12 | Guerbet | Composition destinee a vectoriser un agent anticancereux |
| NZ733010A (en) | 2014-12-31 | 2023-01-27 | Lantheus Medical Imaging Inc | Lipid-encapsulated gas microsphere compositions and related methods |
| FR3039767B1 (fr) | 2015-08-04 | 2017-09-08 | Guerbet Sa | Composition destinee a vectoriser un agent anticancereux |
| IL262647B2 (en) | 2016-05-04 | 2023-03-01 | Lantheus Medical Imaging Inc | Methods and devices for preparing sharpness factors for ultrasound |
| US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
| FR2437831A1 (fr) * | 1978-10-05 | 1980-04-30 | Daeniker Felix | Agent de contraste pour l'examen radiologique du foie et procede pour sa preparation |
| US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957971A (en) * | 1974-07-29 | 1976-05-18 | Lever Brothers Company | Moisturizing units and moisturizing compositions containing the same |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4529561A (en) * | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US4241046A (en) * | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4519024A (en) * | 1983-09-02 | 1985-05-21 | At&T Bell Laboratories | Two-terminal transistor rectifier circuit arrangement |
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US4567034A (en) * | 1984-09-07 | 1986-01-28 | E. R. Squibb & Sons, Inc. | Esters of diatrizoic acid as X-ray contrast agents |
| CH672733A5 (US07261876-20070828-C00017.png) * | 1987-05-22 | 1989-12-29 | Bracco Ind Chimica Spa |
-
1987
- 1987-05-22 CH CH1991/87A patent/CH672733A5/fr not_active IP Right Cessation
-
1988
- 1988-05-16 EP EP88904952A patent/EP0314764B2/en not_active Expired - Lifetime
- 1988-05-16 US US07/302,690 patent/US5312615A/en not_active Expired - Fee Related
- 1988-05-16 DE DE3874485T patent/DE3874485T3/de not_active Expired - Fee Related
- 1988-05-16 ZA ZA883449A patent/ZA883449B/xx unknown
- 1988-05-16 AU AU18054/88A patent/AU612371B2/en not_active Ceased
- 1988-05-16 AT AT88904952T patent/ATE80294T1/de not_active IP Right Cessation
- 1988-05-16 WO PCT/EP1988/000447 patent/WO1988009165A1/en active IP Right Grant
- 1988-05-16 JP JP63504697A patent/JP2619037B2/ja not_active Expired - Fee Related
- 1988-05-17 IL IL86409A patent/IL86409A/xx not_active IP Right Cessation
- 1988-05-20 ES ES8801604A patent/ES2009917A6/es not_active Expired
- 1988-05-20 CA CA000567314A patent/CA1303978C/en not_active Expired - Fee Related
-
1992
- 1992-06-24 MX MX9203271A patent/MX9203271A/es unknown
-
1993
- 1993-09-29 US US08/128,206 patent/US5445810A/en not_active Expired - Fee Related
-
1995
- 1995-05-12 US US08/440,134 patent/US5626832A/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
| FR2437831A1 (fr) * | 1978-10-05 | 1980-04-30 | Daeniker Felix | Agent de contraste pour l'examen radiologique du foie et procede pour sa preparation |
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1805488A (en) | 1988-12-21 |
| CA1303978C (en) | 1992-06-23 |
| US5626832A (en) | 1997-05-06 |
| EP0314764B2 (en) | 2000-02-02 |
| AU612371B2 (en) | 1991-07-11 |
| MX9203271A (es) | 1992-07-01 |
| IL86409A (en) | 1991-12-12 |
| WO1988009165A1 (en) | 1988-12-01 |
| JPH02500192A (ja) | 1990-01-25 |
| EP0314764B1 (en) | 1992-09-09 |
| ES2009917A6 (es) | 1989-10-16 |
| DE3874485D1 (de) | 1992-10-15 |
| EP0314764A1 (en) | 1989-05-10 |
| US5445810A (en) | 1995-08-29 |
| US5312615A (en) | 1994-05-17 |
| ZA883449B (en) | 1988-11-16 |
| ATE80294T1 (de) | 1992-09-15 |
| JP2619037B2 (ja) | 1997-06-11 |
| DE3874485T2 (de) | 1993-03-11 |
| IL86409A0 (en) | 1988-11-15 |
| DE3874485T3 (de) | 2000-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH672733A5 (US07261876-20070828-C00017.png) | ||
| Kweon et al. | Liposomes coloaded with iopamidol/lipiodol as a RES-targeted contrast agent for computed tomography imaging | |
| CN1148812A (zh) | “脂质体” | |
| CA2192712A1 (fr) | Nanoparticules stabilisees et filtrables dans des conditions steriles | |
| US8480952B2 (en) | Method of manufacturing pharmaceutical preparations containing liposomes | |
| EP1003488B1 (fr) | Procede de preparation de nanocapsules de type vesiculaire | |
| EP0731689A1 (de) | Verfahren zur erhöhung der stabilität von hydrophile wirkstoffe enthaltenden liposomensuspensionen | |
| WO2011101602A1 (fr) | Nanoémulsion pour la délivrance d'au moins deux agents d'intérêt | |
| JP3759765B2 (ja) | リポソーム | |
| FR2660864A1 (fr) | Composition de contraste, procede de preparation de cette composition et application a l'imagerie. | |
| JP2005170923A (ja) | リポソーム含有ｘ線造影剤およびその製造方法 | |
| US6217849B1 (en) | Liposome suspensions as blood pool imaging contrast agents | |
| JPH10500999A (ja) | 血液プール画像形成造影剤としてのリポソーム懸濁液 | |
| JPH03504382A (ja) | 高比率活性剤：脂質複合体 | |
| JP2009046441A (ja) | コレステロール誘導体、リポソーム、リポソームの形成方法及びｘ線用造影剤 | |
| JP4649841B2 (ja) | リポソーム含有製剤の製造方法、およびリポソーム含有製剤 | |
| JP2001504837A (ja) | 粒状組成物 | |
| JP2008120721A (ja) | 高比重薬剤を内包したリポソームの製造方法 | |
| JP2005162702A (ja) | リポソーム製剤の製造方法、リポソーム製剤およびその製造装置 | |
| JP2005179214A (ja) | Ｘ線検査用造影剤 | |
| JP2005206540A (ja) | リポソーム含有ｘ線造影剤 | |
| JP2005145845A (ja) | Ｘ線検査用造影剤 | |
| JP2005232053A (ja) | リポソーム含有製剤の製造方法、およびリポソーム含有製剤 | |
| JP2005255588A (ja) | リポソーム含有ｘ線造影剤 | |
| JP2005170928A (ja) | リポソーム含有ｘ線造影剤およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |